Asthma/COPD

• What are Therapeutic Market Outlooks?
• Available Reports
• Pricing and Deliverables
• TMO Sample Pages

Tables and Figures - Asthma/COPD

• Page 4: Main Types of Asthma
• Page 5: Classifications of Asthma
• Page 7: AVOS Asthma and COPD Population Projections by Year
• Page 8: Asthma and COPD Patient Population Model
• Page 12: U.S. Asthma and COPD Market Model, 2004-2013
• Page 13: U.S. Asthma and COPD Market Model, 2004-2013 (Continued)
• Page 14: Treatment Decision Tree: Asthma
• Page 15: Treatment Decision Tree: COPD
• Page 17: Physician Product Ratings (Asthma), Physician Product Ratings (COPD)
• Page 18: AVOS Physician Panel Market Trend Forecasts
• Page 22: Marketed Products in the United States
• Page 23: Timeline of Major Market Events
• Page 24: Advair Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 27: Symbicort Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 29: Spiriva Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 31: Atrovent/Combivent Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 33: Singulair/montelukast Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 35: Xolair Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 37: Asmanex Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 39: Pulmicort Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 41: Flovent Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 43: Serevent Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 45: Foradil Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 47: Brovana Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 49: Albuterol/ProAir HFA/Proventil HFA Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 51: Xopenex HFA Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 53: Alvesco Franchise Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 55: Aclidinium Bromide/Bretaris Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 56: Indacaterol Franchise Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 58: Flutiform Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 60: Asmanex + Foradil Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 61: Clinical Success Rates of Respiratory Agents: 1990-Present
• Page 62: Drugs in Development
• Page 63: Drugs in Development (Continued)